Brenipatide being investigated for alcohol use disorder, while exploring relapse prevention in recurrent depression and other psychiatric conditions.
Rob Nicholson, PhD
Advertisement
Articles by Rob Nicholson, PhD
Phase 1 brenipatide shows week-long exposure and tolerable GI effects, fueling studies in alcohol and other substance use disorders.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Adult ADHD Guidelines: What Resources Are Coming Soon
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
4
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
5